Search Results

Professor Lin Guoxian from the BC Cancer Agency Delivers Academic Exchange at the Institute of Radiation Medicine, Chinese Academy of Medical Sciences

Lin Guoxian: Professor at the BC Cancer Agency, whose research focuses on the development of targeted radiopharmaceuticals for the diagnosis and treatment of various tumors. To date, he has led/participated in the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed the clinical translation of 7 self-developed radiopharmaceuticals for the diagnosis and treatment of multiple tumor types. During the seminar, Professor Lin Guoxian, based on his team's years of frontier exploration, systematically reviewed the research progress of nuclear drugs targeting PSMA for prostate cancer: first, the molecular design and clinical advantages of F-18 labeled PSMA-targeted PET imaging agents; second, the substantial improvement of tumor targeting of Lu-177 labeled therapeutic radiopharmaceuticals through rational optimization of molecular structures,...

2026-08-07

Institute of Radiation Medicine, Chinese Academy of Medical Sciences Hosts Academic Seminar on PSMA-Targeted Radiopharmaceuticals

On August 3, the Institute of Radiation Medicine, Chinese Academy of Medical Sciences held an academic seminar, inviting Professor Lin Guoxian from the BC Cancer Agency in Vancouver, Canada, to deliver a lecture titled "Development of Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals for the Diagnosis and Treatment of Prostate Cancer." The seminar was held in a hybrid format, with some researchers and graduate students from the institute attending in person. Professor Lin Guoxian has long been engaged in the development of targeted radiopharmaceuticals for cancer diagnosis and therapy, having led or contributed to the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed clinical translation of 7 self-developed radiopharmaceuticals applied in...

2026-08-07

South Korea Advances First Domestic Commercial Production of Lu-177 Using Wolsong Heavy Water Reactors

Korea Hydro & Nuclear Power (KHNP) plans to use the heavy water reactors at the Wolsong Nuclear Power Plant to produce, for the first time domestically, the radioisotope lutetium-177 (Lu-177) for cancer treatment. Currently, South Korea relies entirely on imports for this material, which imposes cost pressures and supply instability on local radiopharmaceutical companies such as Cellbion and FutureChem. Industry experts generally believe that domestic production will help build a diversified supply chain and shorten transportation times. The primary goal of this plan is to achieve commercial production of Lu-177, with pilot production expected in 2028 and full-scale production commencing in 2031. Subsequently, KHNP will expand production to include cobalt...

2026-08-06

Argentina's nuclear power generates 4.45 million kWh in half a year, accounting for over 7% of national electricity and meeting the residential electricity needs of 6 million people

Operating data from Nucleoeléctrica Argentina for the first half of 2026 shows that the Atucha 2 and Embalse nuclear power plants generated a combined 4,450,355 kWh, accounting for over 7% of the country's total electricity generation during the period and covering 13% of national residential electricity demand. Notably, although Atucha 1 is temporarily out of service due to a life extension project, the nuclear plants are still able to supply electricity to approximately 6 million people. In addition to its operational breakthroughs, Nucleoeléctrica Argentina is also actively expanding its international business. The company has formally established a new business unit aimed at...

2026-08-06

Vietnam Issues 470 International Nuclear Energy Standards Covering the Full Chain of Nuclear Power Plants, Research Reactors, SMRs, and Radiation Protection

Vietnam is preparing for nuclear energy development, with the Ministry of Science and Technology recently issuing a list of 470 international and foreign standards directly applicable to the atomic energy sector. These standards cover multiple aspects including safety, design, operation, equipment, personnel, radiation protection, nuclear security, and accident response, aiming to ensure the safe and reliable operation of nuclear facilities throughout their entire lifecycle. The list encompasses requirements across a wide range of fields, from nuclear power plants and research reactors to fuel technology, monitoring systems, radioactive waste management, and nuclear security. For nuclear power plants, the standards cover analysis, safety assessment, design, commissioning, equipment classification, accident management, aging management, maintenance...

2026-08-06

Novovoronezh NPP Unit 6 Exceeds 79 Billion kWh in a Decade of Operation

Since Unit 6 of Russia's Novovoronezh Nuclear Power Plant was first connected to the grid in 2016, it has delivered over 79 billion kWh of electricity to the Unified Energy System of Russia. The unit is the world's first Generation III+ nuclear power unit equipped with a VVER-1200 reactor, and also the first new nuclear unit built from scratch in Russia under the NPP-2006 project. The Novovoronezh NPP currently operates four units, namely Units 4, 5, 6, and 7. Unit 6 accounts for 31.2% of the plant's total electricity generation from operating units. The unit entered commercial operation in February 2017. Its construction began in 2007, with about 200 contracting organizations involved in the project. Russia...

2026-08-06

South Korea advances plan to produce medical isotopes using nuclear power plants, with lutetium-177 targeted for commercial production in 2031

South Korea is advancing plans to industrialize the production of radioisotopes using nuclear power plants, with the medical isotope lutetium-177 (Lu-177) designated as the first commercial target product. Korea Hydro & Nuclear Power stated that it plans to prioritize the commercialization of Lu-177 production, with the potential to later expand the product range to include isotopes such as cobalt-60, tritium-3, and helium-3. Lu-177 is a therapeutic radioisotope widely used in the global radiopharmaceutical market, applicable in radiopharmaceuticals for diseases such as prostate cancer and neuroendocrine tumors. Previously, South Korea relied entirely on imports for its Lu-177 supply. Due to its half-life of approximately 6.6 days, the entire process from production and transportation to drug preparation and patient administration...

2026-08-06

TRISO-X Expands Oak Ridge Nuclear Fuel Campus with Approximately 70 Additional Acres

TRISO-X, LLC, a wholly owned subsidiary of X-Energy, Inc., announced on August 4 that it has acquired approximately 70 acres of land near its commercial nuclear fuel campus in Oak Ridge, Tennessee, to support the continued construction and long-term expansion of its fuel manufacturing facility. Following the acquisition, TRISO-X's total campus footprint in the area has expanded to approximately 180 acres. The land acquisition was announced at a meeting of the Oak Ridge Industrial Development Board. The newly acquired land comprises two separate parcels and will provide additional space for utility access, equipment staging, fuel storage, and future...

2026-08-05

Russia Plans to Complete Domestic MRI Scanner Development by 2027

On August 1, Russian Prime Minister Mikhail Mishustin stated that Russia should complete the development of a domestically produced MRI scanner by 2027. Mishustin learned about the relevant progress during his visit to the Consultative Diagnostic Center in the Republic of Tyva. While inspecting the MRI equipment installed at the center, he asked Russian Health Minister Mikhail Murashko about the development of domestic devices. Murashko stated that the research and development work is being carried out by Rosatom, and noted that the device is expected to be completed next year. Mishustin then expressed hope that Russia would have its own domestically developed MRI scanner next year. If the device is completed as planned, it will be used in the field of medical imaging diagnostics.

2026-08-05

Ratio Therapeutics Completes $70 Million Series C Financing to Advance Clinical Development of Ac-225 Targeted Radiopharmaceuticals

Ratio Therapeutics, Inc., a U.S. clinical-stage pharmaceutical company, recently announced the completion of a $70 million Series C financing round. The company stated that following this round, its cumulative total financing has exceeded $240 million. According to the announcement, this round saw participation from existing investors Duquesne Family Office and Bristol Myers Squibb, while also bringing in new investors such as Catalio Capital Management, Eli Lilly and Company, and Wasatch Group. Ratio Therapeutics stated that the proceeds will be used to advance the clinical development of its targeted radiotherapeutic product pipeline and expand manufacturing infrastructure. The company plans to continue advancing the ATLAS study, which is evaluating its lead radiotherapeutic agent [Ac-2...

2026-08-03

Serbia Launches Nuclear Program: Experts to Train in France for 17 Months, First Nuclear Power Plant Expected by 2040

The nuclear cooperation agreement signed between Serbia and France officially launched the first phase of the country's nuclear energy program on July 29. Under the agreement, Serbian experts will travel to France over the next 17 months for training, seminars, and professional visits to acquire the new knowledge and experience needed to advance the nuclear program. Radoš Popadić, Assistant Minister at Serbia's Ministry of Mining and Energy, stated that nuclear energy could become a realistic and viable solution within Serbia's energy mix. The primary task of the first phase is to assess existing capabilities and identify what additional resources are needed as the process moves forward. According to the plan, Serbia needs to strategically...

2026-08-03

Japanese Poll: 76% of Respondents Support Maintaining the "Three Non-Nuclear Principles"

The Tokyo Shimbun, citing a national poll conducted by the Kyodo News-affiliated survey organization from June to July among 3,000 people aged 18 and above, reported that 76% of Japanese support maintaining the Three Non-Nuclear Principles of not manufacturing, not possessing, and not allowing the introduction of nuclear weapons; 77% oppose nuclear-sharing arrangements (i.e., the U.S. stationing nuclear weapons in Japan and operating them jointly). Given that Japan is the only country to have suffered atomic bombing in war, the results highlight strong anti-nuclear sentiment, while debate over whether to revise the principles is intensifying. Support for Japan joining the Treaty on the Prohibition of Nuclear Weapons before the first review conference in November stands at 55%, down 5 percentage points from the previous year; opponents account for 42%, of whom 56% believe that joining would not lead to nuclear disarmament. Regarding recent U.S. actions...

2026-08-03

US FDA Approves Pluvicto Expanded Indication for Treatment of PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer

On July 31, 2026, Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for the treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer. This disease is commonly referred to as metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on results from the Phase III PSMAddition trial. The study showed that compared with standard of care alone, namely ARPI combined with androgen deprivation therapy (ADT), Pluvicto plus standard of care reduced the risk of disease progression or death by...

2026-08-03

Buried Cesium-137 Sealed Source Discovered by Texas Patrol Officer Near Roadside in Midland County

According to the Texas Department of Public Safety, a corporal with the department recently discovered a buried cesium-137 sealed radioactive source with an activity of 100 millicuries during a routine patrol near a roadway in Midland County. The incident resulted in no injuries or radiation contamination, and public safety was not threatened. On July 24 local time, the corporal, assigned to the department's Radioactive/Nuclear Threat Detection Section, was patrolling near South County Road 1210 when the vehicle-mounted radiation detection system activated. He then used other detection equipment to survey the surrounding area and traced the radiation signal to an underground location. To ensure safe disposal, he requested assistance from local, state, and federal...

2026-08-02

U.S. Team Traces Source of Anomalous Gamma Rays from Zinc-70, Nuclear Magnetic Transitions May Improve Models of Heavy Element Formation

An international research team led by scientists from the Facility for Rare Isotope Beams (FRIB) at Michigan State University has recently identified the source of the large number of low-energy gamma rays emitted by zinc-70 nuclei. The study suggests that magnetic transitions occurring within the nucleus are the key reason for this anomalous signal enhancement. The findings were published in the journal Nature under the title "Magnetic character of the low-energy enhancement in 70Zn." Gamma rays are electromagnetic radiation released when excited atomic nuclei transition to lower, more stable energy levels. For a long time, scientists have observed an anomalous increase in the number of low-energy gamma rays in some atomic nuclei, known as the low-energy enhancement (LEE), but its physical mechanism had remained unclear...

2026-08-02